Responses
Clinical and epidemiological research
Concise report
Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study
Compose a Response to This Article
Other responses
No responses have been published for this article.